Smith & Nephew SNATS (SNN) - Stock & Dividends

Exchange: USA Stocks • Country: United Kingdom • Currency: USD • Type: Common Stock • ISIN: US83175M2052

(NYSE:SNN Stock) Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. The company operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products, including instruments, technologies, and implants to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom. Web URL:

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Smith & Nephew SNATS (SNN) - Stock & Dividends

SNN Stock Overview

Market Cap in USD 12,267m
Sector Healthcare
Industry Medical Devices
GiC SubIndustry Health Care Equipment
TER 0.00%
IPO / Inception 1999-11-16

SNN Stock Ratings

Fundamental 3.76
Dividend 5.78
Growth 5y -3.12
Rel. Performance vs Sector -0.99
Analysts 4.50
Fair Price Total Ret. 27.82
Fair Price DCF 1.35

SNN Dividends

Yield 12m 2.62%
Yield on Cost 5y 2.20%
Dividends CAGR 5y 0.60%
Payout Consistency 95.6%

SNN Growth Ratios

Growth 12m 0.45%
Growth Correlation 12m -30%
Growth Correlation 3m 73%
CAGR 5y -3.46%
CAGR / Mean Drawdown -0.13
Sharpe Ratio 12m -0.22
Alpha vs SP500 12m -27.63
Beta vs SP500 5y weekly 1.07
CAPM 8.19%
Average Daily Range 2m 1.31%
Regime Oscillator 72.63
Volatility GJR Garch 1y 23.37%
Price / SMA 50 4%
Price / SMA 200 4.31%
Current Volume 685.7k
Average Volume 20d 955.5k

External Links for SNN Stock

Wall Street JournalBenzingaYahoo Finance
X (Twitter)Stocktwits
Fund Manager Positions
What is the price of SNN stocks?
As of February 22, 2024, the stock is trading at USD 28.58 with a total of 685,725 shares traded.
Over the past week, the price has changed by +3.07%, over one month by +0.63%, over three months by +11.99% and over the past year by +0.07%.
Why is SNN stock down?
Check with which Index or Commodity SNN has the highest Correlation, do they have a common driver?
Review the Fundamentals to find weaknesses (Debt, low returns). Check the Performance of the Peer-Group to find out, if the entire sector is under pressure.
Period Return SNN Return S&P 500
1 Month 0.63% 2.85%
3 Months 11.99% 10.14%
12 Months 0.07% 26.48%
What is the forecast for SNN stock price target?
According to ValueRays Forecast Model, SNN Smith & Nephew SNATS will be worth about 30.2 in February 2025. The stock is currently trading at 28.58. This means that the stock has a potential upside of +5.56%.
Issuer Forecast Upside
Wallstreet Target Price 31.7 10.8%
Analysts Target Price 31.3 9.6%
ValueRay Target Price 30.2 5.6%